MNA
ALXN

Manning & Napier Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Manning & Napier Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,105,568
Closed -$134M – 362
2017
Q1 		$134M Sell
1,105,568
-218,876
-17% -$28.2M 1.04% 40
2016
Q4 		$162M Buy
1,324,444
+1,217,834
+1,142% +$149M 1.06% 36
2016
Q3 		$13.1M Buy
106,610
+11,560
+12% +$1.49M 0.08% 96
2016
Q2 		$11.1M Buy
+95,050
New +$13.5M 0.07% 107

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Manning & Napier Advisors's ALXN Position: Q2 2017 in Review

Manning & Napier Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 1,105,568 shares — an estimated $134M sold.

Manning & Napier Advisors first reported a position in ALXN in Q2 2016 and held it in 4 quarters. The position peaked at $162M in Q4 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

  • Manning & Napier Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Manning & Napier Advisors sold 1,105,568 Alexion Pharmaceuticals shares in Q2 2017, an estimated $134M.
  • Manning & Napier Advisors first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Manning & Napier Advisors's Alexion Pharmaceuticals position peaked at $162M in Q4 2016.
  • 559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Manning & Napier Advisors's 13F filing for Q2 2017, filed 20 Jul 2017.